Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Jacobson Pharma's Enterprise Value is HK$2,655 Mil.
Jacobson Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was HK$393 Mil. Therefore, Jacobson Pharma's EV-to-EBIT ratio for today is 6.75.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Jacobson Pharma's Enterprise Value is HK$2,655 Mil.
Jacobson Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was HK$393 Mil. Therefore, Jacobson Pharma's EV-to-EBITDA ratio for today is 6.75.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Jacobson Pharma's Enterprise Value is HK$2,655 Mil.
Jacobson Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was HK$1,569 Mil. Therefore, Jacobson Pharma's EV-to-Revenue ratio for today is 1.69.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Jacobson Pharma's Enterprise Value is HK$2,655 Mil.
Jacobson Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was HK$192 Mil. Therefore, Jacobson Pharma's EV-to-FCF ratio for today is 13.82.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Jacobson Pharma (HKSE:02633) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Jacobson Pharma's current Enterprise Value is HK$2,655 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Jacobson Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was HK$393 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Jacobson Pharma's current Enterprise Value is HK$2,655 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Jacobson Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was HK$393 Mil.
Jacobson Pharma's current Enterprise Value is HK$2,655 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Jacobson Pharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was HK$1,569 Mil.
Jacobson Pharma's current Enterprise Value is HK$2,655 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Jacobson Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was HK$328 Mil.
Jacobson Pharma's current Enterprise Value is HK$2,655 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Jacobson Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was HK$192 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jacobson Pharma Enterprise Value Related Terms
Jacobson Pharma Enterprise Value Historical Data
* Premium members only.
The historical data trend for Jacobson Pharma's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jacobson Pharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jacobson Pharma Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jacobson Pharma's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Jacobson Pharma's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Jacobson Pharma's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of HK$2,655 Mil mean?
Jacobson Pharma (HKSE:02633) has a Enterprise Value of HK$2,655 Mil as of Sep. 02, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Jacobson Pharma and its competitors.
Is Jacobson Pharma's Enterprise Value too high?
Jacobson Pharma's current Enterprise Value is HK$2,655 Mil. Overall, Jacobson Pharma has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jacobson Pharma's Enterprise Value compare to ZTS?
Jacobson Pharma's Enterprise Value of HK$2,655 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Jacobson Pharma and its competitors. Jacobson Pharma's current Enterprise Value is HK$2,655 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobson Pharma stock overvalued right now?
Based on GuruFocus' analysis, Jacobson Pharma (HKSE:02633) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.85, compared to a current price of HK$1.04 — trading 21.8% above its estimated fair value. The current Enterprise Value is HK$2,655 Mil. Jacobson Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Jacobson Pharma (HKSE:02633), the current Enterprise Value is HK$2,655 Mil as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jacobson Pharma (HKSE:02633) Overvalued in 2026?
Based on GuruFocus' analysis, Jacobson Pharma stock appears to be overvalued.
The current stock price of HK$1.04 is trading 21.8% above its estimated GF Value™ of HK$0.85.
GuruFocus considers Jacobson Pharma to be Modestly Overvalued.
Key valuation signals for HKSE:02633:
Enterprise Value: HK$2,655 Mil
GF Value™: HK$0.85 vs. price of HK$1.04 (21.8% above fair value)
No single metric tells the full story. See the HKSE:02633 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jacobson Pharma Corp Ltd is an investment holding company. It is principally engaged in the development, production, marketing, and sale of generic drugs. The company's operating segment includes Generic drugs; Branded healthcare, Wholesale, and retail The generic drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. It generates maximum revenue from the Generic drugs segment. Geographically, it derives a majority of its revenue from Hong Kong and also has a presence in Mainland China, Macau, Singapore, and Other Countries.
56GF Score
Get the complete analysis for HKSE:02633
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02633 has been successfully added to your 
